You are here

Government

Analysis: Antiviral TPOXX, used for mpox no better than placebo, NIH

The National Institutes of Health said Thursday that an antiviral often used to treat mpox did not resolve patients’ symptoms faster than placebo in a randomized trial.

The results are notable because the drug, tecovirimat, has rarely been studied clinically for mpox, despite its wide use during the 2022 and 2023 outbreaks in the U.S. and Europe.

Problem, Solution, SitRep, or ?: 

Long COVID and disability links highlighted in CDC study

Intersection of long COVID and disability highlighted in CDC study (medicalxpress.com)

Just as coronavirus transmission fluctuated in waves, so too have our responses to it. The world is four years from the acute phase of the pandemic, but not without lasting impact—including those who have maintained debilitating symptoms from COVID, adding to a large population of people with disabilities.

...

The largest study conducted by the CDC to capture the scope of disability in the U.S. and representing 245 million people, the authors found that nearly half of those over 65 reported being disabled, and that long COVID symptoms were present in 11% of those who reported disabilities, versus 7% of those without disabilities.

...

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Government
howdy folks
Page loaded in 1.212 seconds.